Log in with your email address username.


[Comment] Triple therapy for symptomatic patients with COPD

Combination therapy is almost the standard for treating chronic diseases, including chronic obstructive pulmonary disease (COPD).1 Until 2016, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommendation for highly symptomatic COPD patients at risk of exacerbations or severe airflow limitation (GOLD D) was treatment with either long-acting muscarinic antagonists (LAMA) or long-acting β2-agonists (LABA) in combination with inhaled glucocorticosteroids (ICS), both with strong evidence.